Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor
Hidehiro Ishii(Joslin Diabetes Center), Michael R. Jirousek(Eli Lilly (United States)), Daisuke Koya(Joslin Diabetes Center), Chikako Takagi(Joslin Diabetes Center), Pu Xia(Joslin Diabetes Center), Allen C. Clermont(Joslin Diabetes Center), Sven–Erik Bursell(Joslin Diabetes Center), Timothy S. Kern(University of Wisconsin–Madison), Lawrence M. Ballas(SPX Corporation (United States)), William F. Heath(Eli Lilly (United States)), Lawrence E. Stramm(Eli Lilly (United States)), Edward P. Feener(Joslin Diabetes Center), George L. King(Joslin Diabetes Center)
Cited by 1,104
Abstract
The vascular complications of diabetes mellitus have been correlated with enhanced activation of protein kinase C (PKC). LY333531, a specific inhibitor of the beta isoform of PKC, was synthesized and was shown to be a competitive reversible inhibitor of PKC beta 1 and beta 2, with a half-maximal inhibitory constant of approximately 5 nM; this value was one-fiftieth of that for other PKC isoenzymes and one-thousandth of that for non-PKC kinases. When administered orally, LY333531 ameliorated the glomerular filtration rate, albumin excretion rate, and retinal circulation in diabetic rats in a dose-responsive manner, in parallel with its inhibition of PKC activities.
Related Papers
No related papers found
Powered by citation graph analysis